Top

Documenta Ophthalmologica

Published in:

01-10-2016 | Clinical Case Report

Bevacizumab for choroidal neovascularisation in enhanced S-cone syndrome

Authors: G. K. Broadhead, J. R. Grigg, P. McCluskey, M. Korsakova, A. A. Chang

Published in: Documenta Ophthalmologica | Issue 2/2016

Abstract

Introduction

We present a case of enhanced S-cone syndrome (ESCS)-associated choroidal neovascularisation (CNV) treated successfully with intravitreal bevacizumab therapy.

Methods/case report

A 14-year-old with a known retinal dystrophy presented with acute visual deterioration. Fluorescein angiography demonstrated CNV, and treatment was initiated with an anti-vascular endothelial growth factor (anti-VEGF) agent, with significant improvement in vision. Subsequent electroretinogram examination of the patient and her younger sister showed severely reduced rod responses with accentuated fast cone (S-cone only) response, confirming the diagnosis of ESCS as the underlying dystrophy.

Conclusion

CNV is a rare complication of ESCS that is responsive to anti-VEGF therapy. Although cystic retinal lesions may develop in patients with retinal dystrophies due to multiple possible aetiologies, CNV is a known cause of macula oedema in these patients that requires treatment with different agents, namely anti-VEGF therapy. Rapid visual loss in patients with inherited retinal disorders should prompt immediate clinical assessment to exclude CNV, and if CNV is detected, anti-VEGF therapy can preserve vision.

Haider NB, Jacobson SG, Cideciyan AV et al (2000) Mutation of a nuclear receptor gene, NR2E3, causes enhanced S cone syndrome, a disorder of retinal cell fate. Nat Genet 24(2):127–131CrossRefPubMed

Coppieters F, Leroy BP, Beysen D et al (2007) Recurrent mutation in the first zinc finger of the orphan nuclear receptor NR2E3 causes autosomal dominant retinitis pigmentosa. Am J Hum Genet 81(1):147–157CrossRefPubMedPubMedCentral

Hood DC, Cideciyan AV, Roman AJ, Jacobson SG (1995) Enhanced S cone syndrome: evidence for an abnormally large number of S cones. Vis Res 35(10):1473–1481CrossRefPubMed

Audo I, Michaelides M, Robson AG et al (2008) Phenotypic variation in enhanced S-cone syndrome. Invest Ophthalmol Vis Sci 49(5):2082–2093CrossRefPubMed

Marmor MF, Jacobson SG, Foerster MH, Kellner U, Weleber RG (1990) Diagnostic clinical findings of a new syndrome with night blindness, maculopathy, and enhanced S cone sensitivity. Am J Ophthalmol 110(2):124–134CrossRefPubMed

Marano F, Deutman AF, Leys A, Aandekerk AL (2000) Hereditary retinal dystrophies and choroidal neovascularization. Graefe’s archive for clinical and experimental ophthalmology 238(9):760–764CrossRefPubMed

Nakamura M, Hotta Y, Piao CH, Kondo M, Terasaki H, Miyake Y (2002) Enhanced S-cone syndrome with subfoveal neovascularization. Am J Ophthalmol 133(4):575–577CrossRefPubMed

Freund KB, Mrejen S, Gallego-Pinazo R (2013) An update on the pharmacotherapy of neovascular age-related macular degeneration. Expert Opin Pharmacother 14(8):1017–1028CrossRefPubMed

Marmor MF, Fulton AB, Holder GE, Miyake Y, Brigell M, Bach M (2009) ISCEV Standard for full-field clinical electroretinography (2008 update). Doc Ophthalmol 118(1):69–77CrossRefPubMed

10.

Bhutto I, Lutty G (2012) Understanding age-related macular degeneration (AMD): relationships between the photoreceptor/retinal pigment epithelium/Bruch’s membrane/choriocapillaris complex. Mol Aspects Med 33(4):295–317CrossRefPubMedPubMedCentral

11.

Wolfensberger TJ, Chiang RK, Takeuchi A, Marmor MF (2000) Inhibition of membrane-bound carbonic anhydrase enhances subretinal fluid absorption and retinal adhesiveness. Graefe’s archive for clinical and experimental ophthalmology 238(1):76–80CrossRefPubMed

12.

Iannaccone A, Fung KH, Eyestone ME, Stone EM (2009) Treatment of adult-onset acute macular retinoschisis in enhanced s-cone syndrome with oral acetazolamide. Am J Ophthalmol 147(2):307–312CrossRefPubMed

13.

Palejwala NV, Lauer AK, Weleber RG (2014) Choroidemia associated with choroidal neovascularisation treated with intravitreal bevacizumab. Clin Ophthalmol 8:1675–1679CrossRefPubMedPubMedCentral

14.

Kim M, Kim JH, Seo Y, Koh HJ, Lee SC (2015) Intravitreal bevacizumab for traumatic choroidal rupture. Optom Vis Sci 92(10):363–367CrossRef

Title: Bevacizumab for choroidal neovascularisation in enhanced S-cone syndrome
Authors: G. K. Broadhead
J. R. Grigg
P. McCluskey
M. Korsakova
A. A. Chang
Publication date: 01-10-2016
Publisher: Springer Berlin Heidelberg
Published in: Documenta Ophthalmologica / Issue 2/2016
Print ISSN: 0012-4486
Electronic ISSN: 1573-2622
DOI: https://doi.org/10.1007/s10633-016-9555-9

At a glance: The STEP trials

Springer Medicine

Bevacizumab for choroidal neovascularisation in enhanced S-cone syndrome

Abstract

Introduction

Methods/case report

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Introduction

Methods/case report

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2016

Variability of the multifocal electroretinogram based on the type and position of the electrode

A late foveal response component of multifocal electroretinograms in healthy subjects

Transfer characteristics of subretinal visual implants: corneally recorded implant responses

Diagnostic methods in ocular argyrosis: case report

Successful scleral buckling of late-onset visual decrease in eye with retinal folds

Comparison of photopic negative response measurements in the time and time–frequency domains